...
首页> 外文期刊>Beni-Suef University Journal of Basic and Applied Sciences >Preparation and characterization of rilpivirine solid dispersions with the application of enhanced solubility and dissolution rate
【24h】

Preparation and characterization of rilpivirine solid dispersions with the application of enhanced solubility and dissolution rate

机译:利吡韦林固体分散体的制备和表征,具有较高的溶解度和溶解度

获取原文
           

摘要

Rilpivirine (RPV) is a pharmaceutical drug used for the treatment of HIV infection. The drug is characterized with poor aqueous solubility and dissolution rate leading to low bioavailability of the drug. Hence, there is a need for the improvement of the solubility and dissolution of such drugs. In this exertion, enhancement of the solubility and dissolution of the practically water insoluble drug rilpivirine was achieved by solid dispersion (SD) preparation using solvent evaporation method which eventually leads to bioavailability enhancement. SD's were formed using Kollidon VA 64 which is a water-soluble copolymer and varying copolymer ratio to Avicel PH-101, Gelucire 50/13 and lecithin soya. Solubility studies were carried out to establish the solubility-enhancing property of the SD's. To support solubility analysis results, powder dissolution studies were carried out. The SD's were characterized by Fourier transform infrared spectroscopy, differential scanning calorimetry, X-ray powder diffraction studies, scanning electron microscopy. It was found that the SD's formed showed the absence of crystalline nature of the drug and its conversion to amorphous state. The solubility and dissolution of the rilpivirine SD's were enhanced. There is a 14.9 fold increase in solubility for Drug: Kollidan VA 64: Gelucire 50/13 (1:4:1). For Drug: Kollidan VA 64 (1:5), Drug: Kollidan VA 64: Lecithin soya (1:4:1) and Drug: Kollidan VA 64: Avicel PH-101 (1:4:1) it was 5.9, 5.4 and 4.2 respectively. In-vitro drug release kinetics was investigated. This study demonstrates the use of solvent evaporation method for the preparation of SD’S in solubility and dissolution enhancement.
机译:Rilpivirine(RPV)是用于治疗HIV感染的药物。该药物的特征在于水溶性差和溶解速率差,导致药物的生物利用度低。因此,需要改善此类药物的溶解性和溶解性。在此过程中,通过使用溶剂蒸发法的固体分散体(SD)制备,提高了几乎不溶于水的药物rilpivirine的溶解度和溶解度,从而最终提高了生物利用度。 SD是使用Kollidon VA 64形成的,它是一种水溶性共聚物,并且与Avicel PH-101,Gelucire 50/13和卵磷脂大豆的共聚物比率有所不同。进行了溶解度研究以建立SD的溶解度增强性质。为了支持溶解度分析结果,进行了粉末溶解研究。通过傅立叶变换红外光谱,差示扫描量热法,X射线粉末衍射研究,扫描电子显微镜对SD进行表征。发现形成的SD显示出该药物没有结晶性质,并且其转化为非晶态。 rilpivirine SD的溶解度和溶解度提高。药物:Kollidan VA 64:Gelucire 50/13(1:4:1)的溶解度增加了14.9倍。药物:Kollidan VA 64(1:5),药物:Kollidan VA 64:卵磷脂大豆(1:4:1)和药物:Kollidan VA 64:Avicel PH-101(1:4:1)分别为5.9、5.4和4.2。研究了体外药物释放动力学。这项研究证明了使用溶剂蒸发法制备SD’S的溶解度和溶解度增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号